18F-PSMA 1007 PET/CT Metrics for Assessment of Whole- Body Tumor Burden in Patients with Metastatic Prostate Cancer | ||
| SECI Oncology Journal | ||
| Volume 13, Issue 4, October 2025, Pages 287-296 PDF (455.24 K) | ||
| DOI: 10.21608/secioj.2025.459091 | ||
| Abstract | ||
| Background: Conventional assessment based solely on standardized uptake values (SUVs) of individual lesions may inadequately reflect the total tumor burden in patients suffering from metastatic prostate cancer (PCa). Prostate- specific membrane antigen (PSMA)-targeted PET/CT imaging enables the derivation of quantitative volumetric biomarkers that simultaneously reflect lesion volume, number, and metabolic activity. Objective: Our objective was to validate PSMA-total volume (PSMA-TV) and -total lesion (PSMA-TL) as quantitative volumetric biomarkers for whole-body tumor burden in metastatic PCa and assess their relation to PSA and Gleason score (GS) to enhance risk stratification and disease monitoring. Patients and Methods: Thirty-nine individuals with PSMA-positive metastatic PCa were included. Quantitative PET/CT parameters were computed from all probable pathological lesions, encompassing SUVmean, SUVmax, and PSMA- TV/PSMA-TL. Correlations among imaging biomarkers, PSA levels, and GS were examined. Results: Whole-body PSMA parameters exhibited significant moderate relationships with PSA levels (SUVmax: r = 0.55, p = 0.001; SUVmean: r = 0.60, p < 0.001; PSMA-TL: r = 0.60, p < 0.001). Nonetheless, there was a weak association with PSMA-TV: r = 0.31, p = 0.05. Furthermore, PSMA-derived metrics exhibited significant moderate correlations with GS (SUVmax: r = 0.40, p = 0.03; PSMA-TV: r = 0.40, p = 0.02; PSMA-TL: r = 0.40, p = 0.006), whereas a weak correlation with SUVmean: r = 0.30, p = 0.046; Conclusion: Both PSMA-TV/PSMA-TL serve as potential quantitative imaging biomarkers for the volumetric evaluation of tumor burden in metastatic PCa. These measures offer significant insight into intra-lesional PSMA expression and systemic disease activity. | ||
| Keywords | ||
| PSMA PET/CT; Tumor burden; Volumetric biomarkers; Metastatic prostate cancer | ||
|
Statistics Article View: 5 PDF Download: 2 |
||
